Explore

Trendline Trendline
InduPro Therapeutics Names Amanda J. Redig as Chief Medical Officer to Advance Cancer Therapies

InduPro Therapeutics Names Amanda J. Redig as Chief Medical Officer to Advance Cancer Therapies

InduPro Therapeutics Names Amanda J. Redig as Chief Medical Officer to Advance Cancer Therapies
Trendline Trendline
InduPro Therapeutics Appoints Dr. Amanda J. Redig as Chief Medical Officer to Lead Oncology Development

InduPro Therapeutics Appoints Dr. Amanda J. Redig as Chief Medical Officer to Lead Oncology Development

InduPro Therapeutics Appoints Dr. Amanda J. Redig as Chief Medical Officer to Lead Oncology Development
Trendline Trendline
Kura Oncology's New Cancer Drug Shows Promise, Potential $2 Billion Market Opportunity

Kura Oncology's New Cancer Drug Shows Promise, Potential $2 Billion Market Opportunity

Kura Oncology's New Cancer Drug Shows Promise, Potential $2 Billion Market Opportunity
Trendline Trendline
Brenus Pharma's Immunotherapy for Colorectal Cancer Receives FDA IND Approval

Brenus Pharma's Immunotherapy for Colorectal Cancer Receives FDA IND Approval

Brenus Pharma's Immunotherapy for Colorectal Cancer Receives FDA IND Approval
Trendline Trendline
Archeus Technologies Begins Phase 1 Trial for Metastatic Cancer Treatment

Archeus Technologies Begins Phase 1 Trial for Metastatic Cancer Treatment

Archeus Technologies Begins Phase 1 Trial for Metastatic Cancer Treatment
Trendline Trendline
Delphia Therapeutics Appoints David P. Kerstein, M.D., as Chief Medical Officer to Advance Cancer Therapies

Delphia Therapeutics Appoints David P. Kerstein, M.D., as Chief Medical Officer to Advance Cancer Therapies

Delphia Therapeutics Appoints David P. Kerstein, M.D., as Chief Medical Officer to Advance Cancer Therapies
Trendline Trendline
Delphia Therapeutics Appoints David P. Kerstein as Chief Medical Officer to Advance Cancer Therapies

Delphia Therapeutics Appoints David P. Kerstein as Chief Medical Officer to Advance Cancer Therapies

Delphia Therapeutics Appoints David P. Kerstein as Chief Medical Officer to Advance Cancer Therapies
Trendline Trendline
Antengene Initiates Phase III Study for ATG-022 in Advanced Gastric Cancer

Antengene Initiates Phase III Study for ATG-022 in Advanced Gastric Cancer

Antengene Initiates Phase III Study for ATG-022 in Advanced Gastric Cancer
Trendline Trendline
Adcendo and MSD Collaborate on Phase Ib Study for Advanced Solid Tumors

Adcendo and MSD Collaborate on Phase Ib Study for Advanced Solid Tumors

Adcendo and MSD Collaborate on Phase Ib Study for Advanced Solid Tumors
Trendline Trendline
IDEAYA Biosciences to Participate in 2026 Jefferies Global Healthcare Conference Highlighting Precision Medicine Advances

IDEAYA Biosciences to Participate in 2026 Jefferies Global Healthcare Conference Highlighting Precision Medicine Advances

IDEAYA Biosciences to Participate in 2026 Jefferies Global Healthcare Conference Highlighting Precision Medicine Advances
Trendline Trendline
Archeus Technologies Initiates Phase 1 Study of ARC-706 for Metastatic Cancer

Archeus Technologies Initiates Phase 1 Study of ARC-706 for Metastatic Cancer

Archeus Technologies Initiates Phase 1 Study of ARC-706 for Metastatic Cancer
Trendline Trendline
Citius Oncology Presents Promising Phase 1 Data on LYMPHIR at ASCO Meeting

Citius Oncology Presents Promising Phase 1 Data on LYMPHIR at ASCO Meeting

Citius Oncology Presents Promising Phase 1 Data on LYMPHIR at ASCO Meeting